二酢酸カルシウム

Cosmetic ingredients (Calcium Acetate) -> CIR (Cosmetic Ingredient Review)

Viscosity controlling

6,0-9,0 (10 % aqueous solution)

0.2 molar aq soln: 7.6 /Monohydrate form/

1.50 kg/l

1.5 g/cm³

1.5 @25 °C

COLORLESS CRYSTALS

Rod-shaped crystals

White, hydrogroscopic, crystalline solid

37.4 G IN 100 CC OF WATER @ 0 °C; 29.7 G IN 100 CC OF WATER @ 100 °C; SLIGHTLY SOL IN ALCOHOL

Practically insol in acetone and benzene

Solubility in water: very good

FDA approved drugs -> Active ingredient

This chemical does not meet GHS hazard criteria for 88.9% (503 of 566) of all reports.

Warning

H315 (11%): Causes skin irritation [Warning Skin corrosion/irritation]

P264, P264+P265, P280, P302+P352, P305+P351+P338, P321, P332+P317, P337+P317, and P362+P364 (click each P-code to see the statement)

Aggregated GHS information provided per 566 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Chemical: Acetic acid, calcium salt (2:1)

Directive (EC) No 46/2002

Acetic acid, calcium salt (2:1) is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Acetic acid, calcium salt (2:1) are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)

Status: Active Update: 27-04-2023 https://echa.europa.eu/registration-dossier/-/registered-dossier/13608

Calcium acetate: Non hazardous

Substance added directly to human food affirmed as generally recognized as safe (GRAS).

Calcium acetate is an indirect food additive for use as a component of resinous and polymeric coatings.

V - Various

QV - Various

Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.

CALCAREA ACETICA

Increased Coagulation Factor Activity [PE]; Blood Coagulation Factor [EPC]; Cations, Divalent [CS]; Calcium [CS]

CALCIUM ACETATE

Blood Coagulation Factor [EPC]; Phosphate Binder [EPC]; Increased Coagulation Factor Activity [PE]; Phosphate Chelating Activity [MoA]; Calcium [CS]; Cations, Divalent [CS]